11 Analysts Have This to Say About Crinetics Pharmaceuticals
Portfolio Pulse from Benzinga Insights
11 analysts have given their ratings on Crinetics Pharmaceuticals (NASDAQ:CRNX) in the last quarter, with 4 being bullish and 7 somewhat bullish. The average price target is $40.73, representing an upside from the current price of $27.55. This average is a 3.78% decrease from the previous average price target of $42.33.
October 24, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts are generally bullish on Crinetics Pharmaceuticals (NASDAQ:CRNX) with an average price target of $40.73, indicating potential upside.
The bullish ratings from 11 analysts and the average price target above the current price indicate a positive outlook for Crinetics Pharmaceuticals. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100